STOCK TITAN

Paratek Pharmace Stock Price, News & Analysis

PRTK Nasdaq

Welcome to our dedicated page for Paratek Pharmace news (Ticker: PRTK), a resource for investors and traders seeking the latest updates and insights on Paratek Pharmace stock.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical innovator developing advanced therapies for complex infectious diseases. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical research, and strategic initiatives driving antibiotic development.

Key resources include: NUZYRA® treatment advancements, partnership announcements with global health organizations, and progress in addressing antimicrobial resistance. Track updates on pulmonary anthrax preparedness programs and international expansion efforts through our verified news collection.

Discover official communications about Paratek's pipeline developments, including non-tuberculous mycobacterial disease research and antibiotic stewardship programs. All content is sourced from regulatory filings and verified news outlets to ensure reliability for investment analysis and medical research.

Bookmark this page for streamlined access to Paratek's latest achievements in combating life-threatening infections through innovative tetracycline-derived therapies. Check regularly for updates on FDA interactions, European market authorizations, and clinical trial outcomes.

Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced on September 30, 2022, the granting of stock options and restricted stock units to twenty new employees. The stock options allow acquisition of 27,600 shares at an exercise price of $2.57, vesting over four years. Additionally, 32,100 shares in restricted stock units will vest after 36 months. This is part of the 2017 Inducement Plan approved by the board to attract employees. Paratek focuses on developing therapies for serious diseases and markets NUZYRA® and SEYSARA® for treating bacterial infections and acne, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.21%
Tags
none
-
Rhea-AI Summary

Paratek Pharmaceuticals will host an investor webinar on October 3, 2022, from 10:30 a.m. to noon ET, to discuss the global opportunity for NUZYRA® (omadacycline) in treating non-tuberculous mycobacteria (NTM). CEO Evan Loh and COO Randy Brenner will cover market insights and scientific updates, including a Phase 2b study in patients with NTM pulmonary disease. Featured speakers include Dr. Patrick Flume and Dr. Jakko van Ingen, who will address NTM challenges in the U.S. and globally. The webinar will be available for on-demand viewing until April 3, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences
-
Rhea-AI Summary

On August 31, 2022, Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced the granting of stock options to a new employee. This award, totaling 3,400 shares at an exercise price of $2.51, is part of its 2017 Inducement Plan and is aimed at attracting talent. The options will vest over four years, with an initial 25% vesting after 12 months. Paratek focuses on developing therapies for severe diseases, with its lead product, NUZYRA®, approved for treating bacterial infections. The company is also engaged in a Phase 2b study for a rare disease, estimating a $1 billion market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
Rhea-AI Summary

BOSTON, Sept. 01, 2022 – Paratek Pharmaceuticals (Nasdaq: PRTK) announced President Adam Woodrow will speak at the H.C. Wainwright 24th Annual Global Investment Conference from Sept. 12-14. The conference will feature a virtual fireside chat accessible on-demand starting Sept. 12 at 7 a.m. ET. Paratek specializes in developing life-saving therapies, with its lead product NUZYRA® approved for treating bacterial pneumonia and skin infections. The company also conducts a Phase 2b study for NUZYRA targeting non-tuberculous mycobacterial pulmonary disease, estimating a $1 billion market opportunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
Rhea-AI Summary

Paratek Pharmaceuticals reported Q2 2022 financial results, showing total revenue of $29.6 million, a significant rise from $19.6 million year-over-year. The core commercial business for NUZYRA generated $25.1 million in net U.S. sales, up 68% from the prior period. Despite this growth, the company reported a net loss of $17.6 million, or $(0.33) per share. Paratek anticipates its cash reserves of $69.4 million will sustain operations through the end of 2023. The FDA granted Fast Track designation for NUZYRA in treating Non-Tuberculous Mycobacteria (NTM), further enhancing its product pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced the grant of stock options to 14 new employees on July 29, 2022. The options, totaling 17,200 shares, have an exercise price of $2.29, aligning with the closing sales price on that date. The options will vest over four years, commencing with 25% after 12 months. Paratek is focused on developing life-saving therapies, with its lead product, NUZYRA®, approved for treating community-acquired bacterial pneumonia and acute bacterial skin infections. The company is also conducting a Phase 2b study for nontuberculous mycobacterial pulmonary disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
none
Rhea-AI Summary

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) will host a conference call and webcast on Aug. 3, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results. Investors can access the event via the company’s website. Paratek focuses on developing life-saving therapies, including its lead product NUZYRA® (omadacycline) for bacterial infections. The company also conducts a Phase 2b study for NUZYRA in nontuberculous mycobacterial pulmonary disease, which represents a potential $1 billion market. Paratek has a BARDA contract valued at up to $304 million for NUZYRA's development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences earnings
-
Rhea-AI Summary

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced the granting of stock options and restricted stock units to 33 new employees on June 30, 2022. Under the 2017 Inducement Plan, a total of 28,800 stock options and 96,200 restricted stock units were awarded. The stock options have an exercise price of $1.93 and vest over four years, while the restricted stock units will vest fully after 36 months. The awards are part of the company’s strategy to incentivize employee retention and growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced that the FDA granted Fast Track designation for NUZYRA® (omadacycline) for treating pulmonary Nontuberculous Mycobacterial (NTM) disease caused by Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB). This designation allows for expedited development and review, addressing significant unmet medical needs. Currently, NTM infections affect approximately 111,500 patients in the U.S. alone. Paratek is conducting a Phase 2b study with about 75 patients enrolled to assess the safety and efficacy of NUZYRA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced the grant of stock options and restricted stock units to twelve new employees on May 31, 2022. The options total 5,200 shares at an exercise price of $1.89, vesting over four years. Additionally, 78,200 restricted stock units will vest after 36 months of employment. These grants align with Paratek's 2017 Inducement Plan, supporting employee retention and recruitment. The company focuses on developing life-saving therapies, including NUZYRA for bacterial infections and SEYSARA for acne vulgaris.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none

FAQ

What is the market cap of Paratek Pharmace (PRTK)?

The market cap of Paratek Pharmace (PRTK) is approximately 127.8M.
Paratek Pharmace

Nasdaq:PRTK

PRTK Rankings

PRTK Stock Data

127.83M
45.60M
11.7%
55.08%
4.6%
Biotechnology
Healthcare
Link
United States
Boston